Publications by authors named "Grady Day"
Article Synopsis
- In situ vaccination (ISV) effectively stimulates an immune response against tumor antigens at a single site, leading to systemic effects in patients with low-grade lymphoma.
- The Phase 1/2 trial results showed a 50% overall response rate with only low-grade adverse events, highlighting one complete response and tumor reduction in all patients at distant sites.
- Single-cell analysis indicated a positive correlation between clinical outcomes and specific immune changes, with enhanced T-cell activity and reduced immune suppression playing critical roles in the treatment's effectiveness.
An early event in the genesis of follicular lymphoma (FL) is the acquisition of new glycosylation motifs in the B-cell receptor (BCR) due to gene rearrangement and/or somatic hypermutation. These N-linked glycosylation motifs (N-motifs) contain mannose-terminated glycans and can interact with lectins in the tumor microenvironment, activating the tumor BCR pathway. N-motifs are stable during FL evolution, suggesting that FL tumor cells are dependent on them for their survival.
View Article and Find Full Text PDFTumor heterogeneity complicates biomarker development and fosters drug resistance in solid malignancies. In lymphoma, our knowledge of site-to-site heterogeneity and its clinical implications is still limited. Here, we profiled 2 nodal, synchronously acquired tumor samples from 10 patients with follicular lymphoma (FL) using single-cell RNA, B-cell receptor (BCR) and T-cell receptor sequencing, and flow cytometry.
View Article and Find Full Text PDF